Q2 2026 Mobia Medical Inc Earnings Call Transcript
Key Points
- Revenue grew 102% year-over-year to $13.5 million in Q2 2026, with full-year guidance of $54-56 million (69-75% growth).
- Gross margin improved to 83.2% in Q2 2026, up from 82.3% in the prior year.
- Successful IPO raised $134 million in net proceeds, strengthening the balance sheet with $177.1 million in cash.
- Expanded geographic footprint to 35.5 average active territories, a 92% increase year-over-year.
- Published 2-year follow-up data in Neurology, demonstrating durable and clinically meaningful improvements in upper limb function.
- Net loss widened to $21.0 million in Q2 2026, up from $10.5 million in Q2 2025.
- SG&A expenses increased 85% year-over-year to $26.9 million, driven by commercial expansion and IPO-related costs.
- R&D expenses rose 61% year-over-year to $2.3 million, reflecting increased headcount.
- The New Tech APC 1580 reimbursement is still a proposal, with final CMS decision pending until November.
- Coverage development with commercial payers is expected to take years, limiting near-term patient access.
Good afternoon, and welcome to the Mobia Medical second-quarter 2026 earnings conference call. (Operator Instructions) Please note that today's conference is being recorded.
I would now like to turn the call over to Louisa Smith of Gilmartin Group, Investor Relations for Mobia Medical. Louisa, please go ahead.
Good afternoon, and thank you for being on today's call. Joining me from Mobia Medical are Richard Foust, President and Chief Executive Officer; and Bunker Curnes, Chief Financial Officer. Earlier today, Mobia Medical issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release is available on the Investor Relations section of the company's website.
Before we begin, I would like to remind you that management will make remarks during this call that constitute forward-looking statements within the meaning of the federal securities laws and that are being made pursuant to the Safe Harbor provisions of the Private Securities Litigation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
